Emerging carbapenemase Klebsiella oxytoca with multidrug resistance implicated in urinary tract infection

Abstract

Background: At present, Klebsiella oxytoca is emerging as a crucial persisted bacterial pathogen in urinary tract infection (UTI), which causes true public health problems worldwide. This study aimed to detect the incidence of K. oxytoca in patients severe from UTI with antibiotic sensitivity tests that assist urologist doctors for appropriate empirical antimicrobial therapy for this bacterium. Methods: K. oxytoca isolated clinically from urine samples during the period from January 2018 to December 2019 at the Al-Shomally General Hospital, Babil, Iraq, and a private laboratory in Babil city. A total of 430 patients were involved in this study; urine samples were processed at the hospital laboratory during this period; and a diagnosis has been done by the routine bacteriological diagnosis as well as VITEK® 2 system. Results: Of these 430 urine samples, 122 had bacterial growth; two types of Klebsiella species have been isolated in 18 patients (14.75%) of total specimens; K. pneumonia detected in 16 patients (89%); and K. oxytoca in 2 patients (11%) of the total Klebsiella species. Escherichia coli was the most prevalent bacteria (56; 45.90%). K. oxytoca UTI isolates were sensitive to amikacin, trimethoprim, and ciprofloxacin. However, these isolates showed resistance to amoxicillin, cefotazidime, clindamycin, nitrofurantoin, and cefotaxime. Conclusion: The current study showed an increasing burden of UTI caused by K. oxytoca. Multidrug resistance is associated with K. oxytoca implicated in UTI that causes changeable sensitivity to various antimicrobial agents.